Toronto-based Tm Bioscience last week launched its Tag-It CYP450-2D6 mutation detection kit — within days after Roche officially introduced its Affymetrix-platform diagnostic CYP450 GeneChip tests to great fanfare in the mainstream media.

“This [P450-2D6] is a rapidly growing test market for the pharmaceutical and the clinical sectors,” said Jeremy Bridge-Cook, Tm Bioscience vice president for business development. He told BioArray News that Tm is looking to compete with Roche and other test-makers on the basis of cost and efficiency.

Get the full story with GenomeWeb Premium

Only $95 for the first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.